Breaks Categories: News

WednesdayAug 02, 2017 10:22 am

HempNewsBreaks – Dow Clinches New Record, Surpassing 22,000 with Boost from Apple (NASDAQ: AAPL)

The Dow Jones Industrial Average this morning rocketed past the 22,000 mark, clipping a new milestone with a boost from Apple, Inc. (NASDAQ: AAPL). Shares of the tech giant are up 5.7% at a new 52-week high of $158.67 in morning trade. The Dow earlier this year crossed the 20,000 mark for the first time in its 120-year history and currently moves in a 52-week range of 17,883.56-22,036.10. For more on the Dow’s record performance, visit: http://nnw.fm/M1Skp More from HempNewsBreaks ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton EyeGate Pharmaceuticals, Inc. (NASDAQ:…

Continue Reading

WednesdayAug 02, 2017 9:04 am

HempNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the completion of Cannabis Wheaton Income Corp.’s (TSX.V: CBW) previously detailed purchase of $15 million of ABcann common shares at an agreed upon valuation of $2.25 per share. “We are pleased to have completed the initial funding phase of our partnership with Cannabis Wheaton and to welcome them as new equity holders in ABcann,” Aaron Keay, chief executive officer of ABcann, stated in the news release. “The initial investment represents Cannabis Wheaton's first funding allocation and we look forward to future investment from them, as both companies advance our respective…

Continue Reading

TuesdayAug 01, 2017 12:08 pm

HempNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Enrolls First Patient in Phase 2b Trial of EGP-437 for Cataract Surgery

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are down 8% in mid-day trade. The specialty pharmaceutical company this morning said it has enrolled the first patient in the phase 2b clinical trial to evaluate its EyeGate® II Delivery System and EGP-437 combination product for the treatment of pain and inflammation in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens). Top-line data is anticipated by year-end 2017. Under an exclusive worldwide licensing agreement signed with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier this year, a subsidiary of Valeant has commercial and manufacturing rights to…

Continue Reading

TuesdayAug 01, 2017 12:06 pm

HempNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Inks Binding LOI for Merger Transaction with CytoBioscience

Skyline Medical (NASDAQ: SKLN) shares are up 4% this morning on news that the company has signed a binding letter of intent for a merger transaction with CytoBioscience, a privately held biomedical company. CytoBioscience is a creator and manufacturer of devices used in human cell research and is focused on new therapeutic drug development. CytoBioscience also has relationships with hospitals and government entities that it aims to leverage to open new markets for Skyline Medical’s STREAMWAY® System operating room safety products. “This is a great opportunity for both companies. The CytoBioscience group has a deep pipeline of projects and contracts…

Continue Reading

TuesdayAug 01, 2017 9:02 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for…

Continue Reading

FridayJul 28, 2017 9:22 am

HempNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment

Cannabis Wheaton Income Corp. (TSX.V: CBW) this morning announced that it has received approval from the TSX Venture Exchange to purchase $15 million of common shares of ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) at an agreed upon valuation of $2.25 per share. Per the update, this investment forms a portion of a larger phased investment by Cannabis Wheaton aimed at funding the construction of ABcann’s proposed 50,000 square foot addition to its Kimmett cannabis cultivation facility to be located in Napanee, Ontario. This morning’s announcement follows the two companies’ entry into a binding interim agreement on May 29, 2017,…

Continue Reading

ThursdayJul 27, 2017 9:23 am

HempNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Research Published in the European Journal of Pain

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the publication of company-sponsored research in the European Journal of Pain. The article, titled ‘Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation’, highlights results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship Program. “Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the 'holy grails' in the field of analgesia,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “This…

Continue Reading

WednesdayJul 26, 2017 9:23 am

HempNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Issues Update on Construction and Expansion Activities

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning provided an update on its construction and expansion timelines for its Vanluven and Kimmett facilities, both of which are located in Napanee, Ontario. Per the update, ABcann’s plans to commence construction at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot Phase 1 project have been expanded to 100,000 square feet. Additionally, the company has initiated immediate expansion and construction efforts at its current production facility at Vanluven with the goal of doubling production capacity in order to…

Continue Reading

MondayJul 24, 2017 9:40 am

HempNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Subsidiary Files Record of ‘CBD Magic Hemp Series’ Product Line Ahead of Impending Launch

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). These products, which comprise the new ‘CBD Magic Hemp Series’ skin care line, are expected to launch in late August and early September of this year, positioning CBD Biotechnology as a first-mover in an untapped segment of China’s skin care industry. “As one of the first skin care products containing CBD extract marketed in China, CBD Magic Hemp…

Continue Reading

ThursdayJul 20, 2017 9:05 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be…

Continue Reading